Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jul 30;12(8):ofaf416.
doi: 10.1093/ofid/ofaf416. eCollection 2025 Aug.

The Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by Enterococcus spp

Federico Frondizi  1 , Gabriele Maria Leanza  1 , Marta Chiuchiarelli  2 , Francesca Catania  1 , Flavio Sangiorgi  1   3 , Francesca Giovannenze  2 , Eleonora Taddei  2 , Enrica Tamburrini  1   2 , Carlo Torti  1   2 , Giancarlo Scoppettuolo  2
Affiliations
Clinical Trial

The Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by Enterococcus spp

Federico Frondizi et al. Open Forum Infect Dis. .

Abstract

Oritavancin is emerging as a potential alternative to standard antibiotic regimens in the treatment of infective endocarditis caused by gram-positive bacteria, though evidence remains limited. We hereby report 7 cases of enterococcal endocarditis treated with oritavancin as consolidation therapy, resulting in 6 cures and 1 relapse.

Keywords: Enterococcus; endocarditis; oritavancin.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. The authors declare no conflicts of interest.

References

    1. Tran TT, Gomez Villegas S, Aitken SL, et al. New perspectives on antimicrobial agents: long-acting lipoglycopeptides. Antimicrob Agents Chemother 2022; 66:e02614–20. - PMC - PubMed
    1. Bassetti M, Labate L, Vena A, Giacobbe DR. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications. Curr Opin Infect Dis 2021; 34:96–108. - PubMed
    1. Baiardi G, Cameran Caviglia M, Piras F, et al. The clinical efficacy of multidose oritavancin: a systematic review. Antibiotics 2023; 12:1498. - PMC - PubMed
    1. Lupia T, De Benedetto I, Bosio R, Shbaklo N, De Rosa FG, Corcione S. Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans: narrative review and possible developments. Life 2023; 13:959. - PMC - PubMed
    1. Johnson JA, Feeney ER, Kubiak DW, Corey GR. Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis. Open Forum Infect Dis 2015; 2:ofv156. - PMC - PubMed

Publication types